Adaptive Biotechnologies and Genentech will partner through a $300 million licensing arrangement for the development of personalized cancer therapies, with Adaptive possibly gaining up to $2 billion upon completion of certain milestones, as well as potential sales royalties. Genentech will take charge of clinical development, regulatory approval and commercialization of the treatments, while Adaptive will supply patient-screening capabilities.
Genentech, Adaptive enter $300M cancer therapies licensing deal
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.